The Top 5 Biosimilars Articles for the Week of March 19

March 23, 2018

The Center for Biosimilars® recaps the top 5 biosimilars articles for the week of March 19, 2018.

Transcript:

Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of March 19.

Number 5: In the latest episode of our podcast, “Not So Different,” Christine Simmon of the Biosimilars Council explains why her organization supports the CREATES Act.

Number 4: Celltrion has granted marketing rights for its trastuzumab in 7 European nations to Mundipharma.

Number 3: A recent study showed that patients with rheumatoid arthritis who use infliximab have a higher discontinuation rate due to disease remission than those patients who use other biologics.

Number 2: The FDA’s Center for Drug Evaluation and Research has launched its pilot effort to publicly release clinical study report data from pivotal clinical trials.

Number 1: An insurer is backing away from a plan to institute a nonmedical switch from brand-name Remicade to biosimilar Inflectra.

Finally, last week, our e-newsletter asked for your thoughts on which stakeholder group has the most influence on biosimilar acceptance.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Content:

News | Business | Policy | Practice | Regulatory

x